Sellas Life Sciences

SELLAS™ Life Sciences Announces Positive Interim Phase II Results from its WT1 Immunotherapeutic Anti-cancer Treatment in Multiple Myeloma Patients

Data Indicates Meaningful Clinical Benefit in High-risk Multiple Myeloma Patients ZUG, Switzerland and NEW YORK, NY, October 13, 2016 /PRNewswire/ — SELLAS Life Sciences Group (SELLAS or the Company), a late-stage biopharmaceutical company focused on the development of novel...
Read More →